Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2022C522 Product name: Pegcetacoplan

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
2022C/522
Type:
Certificate
SPC type:
Medical
Basic patent number:
192054260
Status:
Open & Published
Publication number:
2022C522
1rst applicant's nationality:
Procedural language:
Dutch

Marketing authorization

Marketing authorization number:
EU/1/21/1595
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
14/12/2021
Marketing authorization status:
Accepted
Marketing authorization country:
Belgium (BE)

Dates

Filing date:
10/06/2022
First marketing authorization date:
14/12/2021
Grant date:
Activation date:
BE Publication date:
13/06/2022
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
14/12/2036
SPC/SPC Extension Expiration (if granted and all annual fees paid):
14/12/2036
Rejection date:
Withdrawal date:

Applicant

Name:
Apellis Pharmaceuticals, Inc.
Legal Form:
Inc.
From:
13/06/2022
Address:
100 5th Avenue, 02451, Waltham, Massachusetts, United States (US)
To:

Agent

1

Name:
NLO
Legal Form:
From:
27/11/2024
Address:
New Babylon City Offices Anna van Buerenplein 21A, 2595 DA DEN HAAG, Netherlands (NL)
To:

2

Name:
NLO
Legal Form:
From:
11/06/2022
Address:
Technologiepark 122, 9052, ZWIJNAARDE - GENT, Belgium (BE)
To:
27/11/2024

Publication

Bulletin

Bulletin heading:
SPC
Journal edition number:
2022/11
Publication date:
23/06/2022
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

Annual fee

Annual fee(s) Due Date:
30/11/2033
Annual fee number:
21
Annual fee amount:
650 Euro
Expected payer:
Last annual fee payment date:
Last annual fee paid number:
Payer:
Filing date Document type Publication Type Document Description Number of pages File Type
13/06/2022 Outgoing Correspondence 2 PDF /0/5/1/2/3/0722232150/docs/2022c522_0_outgoingcorrespondence_20220620_015338203.pdf
10/06/2022 Abstract Product Characteristics Abstract of the characteristics of the product 42 PDF /0/5/1/2/3/0722232150/docs/2022c522_1_abstractproductcharacteristics_20220611_084659753.pdf
10/06/2022 Marketing Authorization 1st Marketing Authorization (EU) 3 PDF /0/5/1/2/3/0722232150/docs/2022c522_2_marketingauthorization_20220611_084702226.pdf
10/06/2022 MA Official Publication Official Publication of 1st Marketing Authorization 2 PDF /0/5/1/2/3/0722232150/docs/2022c522_3_maofficialpublication_20220611_084701788.pdf
10/06/2022 Application Form 4 PDF /0/5/1/2/3/0722232150/docs/2022c522_4_applicationform_20220611_084702457.pdf
13/06/2022 Publication I1 1 PDF /0/5/1/2/3/0722232150/docs/2022c522_5_i1document_20220613_091748702.pdf
27/11/2024 Request For Change Letter and/or Form requesting a change in the Register 2 PDF /0/5/1/2/3/0722232150/docs/2022c522_6_rfc_20241127_012947133.pdf
27/11/2024 Outgoing Correspondence Outgoing Correspondence 2 PDF /0/5/1/2/3/0722232150/docs/2022c522_7_206455_pie.rfc.per.notif.pdf